GH-axis research
CJC-1295 No DAC / Ipamorelin
Peptide di ricerca liofilizzato sulla segnalazione endocrina per la revisione dei sistemi
CJC-1295 No DAC / Ipamorelin pairs a shorter-exposure GHRH analog with a selective ghrelin receptor secretagogue in one GH-axis research format.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesSolo per ricerca di laboratorio. Non per uso umano o veterinario. Non destinato a diagnosticare, trattare, curare, mitigare o prevenire malattie.
Conservare sigillato, freddo, asciutto e protetto dagli sbalzi di calore. Conferma lo stoccaggio specifico del prodotto all'arrivo.
Imballato per garantire la stabilità del transito con supporto per gli ordini disponibile per le rotte con clima caldo.
Batch-linked certificate support is available through the documentation desk.
Contesto di ricerca
Profilo di ricerca CJC-1295 No DAC / Ipamorelin
CJC-1295 No DAC / Ipamorelin combines two distinct GH-axis research approaches. The CJC component in this listing is the No DAC form: a shorter-exposure GHRH analog that acts at the GHRH receptor, not the DAC-modified albumin-binding version. Ipamorelin is a ghrelin-receptor secretagogue studied at GHS-R. Research commonly examines how these complementary upstream signals affect GH-release patterns, IGF-1 markers, receptor selectivity, pharmacokinetics, or endocrine feedback differently from either component alone. Component studies provide useful context but do not establish the behavior or synergy of a combined catalog product.
Molecular class
Two-peptide GH-axis combination
Sequence / composition
CJC-1295 No DAC, a modified GHRH analog without a Drug Affinity Complex, paired with the five-residue ghrelin-receptor secretagogue ipamorelin; it is not a single sequence.
Research design note
The No-DAC CJC form and component ratio are defined features of this listing when comparing upstream GHRH-receptor and GHS-R signaling.
Meccanismo proposto
Combines shorter-exposure GHRH-receptor agonism from the CJC-1295 No DAC component with GHS-R1a agonism from ipamorelin. Both converge on pituitary growth-hormone release through different upstream receptors, creating a proposed complementary secretagogue model.
Effetti riportati negli studi
- No-DAC GHRH-analog studies examine acute pituitary response, pulse timing, and GH or IGF-1-related markers under the conditions tested.
- Ipamorelin studies reported dose-related GH release with a selectivity profile different from older GHRP compounds.
- The combination itself lacks strong independent evidence demonstrating synergy, a predictable pulse pattern, or improved outcomes over the separate components.
Endpoint di ricerca comuni
CJC No DAC identity, GHRH receptor response, GHS-R response, GH pulse amplitude and duration, IGF-1, ACTH, cortisol, prolactin, pharmacokinetics, and component controls.
Evidenze e limiti
The literature must be matched to the specified No-DAC CJC component and ipamorelin. Blend-specific effects and equivalence to individual study materials are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.